Food and Drug Administration Weighs Rule Permitting Specialized Pharmacies to Compound Peptide Therapies
Federal health officials are advancing a deregulatory plan that would allow compounding pharmacies to prepare peptide-based treatments, a move supported by alternative medicine advocates but opposed by brand-name pharmaceutical firms that cite potential safety and quality issues.